



## Post Authorisation Assessments

### Eurican Lmulti Suspension for Injection

Vm 08327/4264

•	11 April 2023	Change in the name or address or contact details of a qualified person for pharmacovigilance.
•	21 February 2023	To address a commitment taken during the marketing authorisation procedure of the Eurican Lmulti vaccine and associated vaccines, to replace the in vivo potency test with an in vitro alternative.
•	22 October 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.
•	14 January 2021	Deletion of manufacturing site for an active substance.
•	26 November 2020	Change in the name of the manufacturer of the finished product.
•	09 September 2020	Renewal – UK as CMS
•	22 July 2020	Change in the name of a manufacturer of the active substance.
•	18 June 2020	Change in the name of the manufacturer of the finished product.
•	27 May 2020	Change in the name of a manufacturer of the finished product, also responsible for batch release.
•	05 November 2019	Change in the safety database of an existing pharmacovigilance system as described in the DDPS.
•	21 February 2019	Change of a test procedure for the active substance.
•	16 November 2018	Change in the name and address of the marketing authorisation holder from Merial Animal Health Limited, Sandringham House, Sandringham Avenue, Harlow Business Park, Harlow, Essex, CM19 5TG, United Kingdom to Boehringer Ingelheim Animal Health UK Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom.
•	09 March 2018	Change in the SPC, labelling or package leaflet due to new data.
•	01 June 2017	Approval of mock-ups following the addition of Croatian text.
•	29 November 2016	Addition of a manufacturer as an alternative site for the production of an active ingredient.
•	27 July 2016	Increase in the shelf life of the finished product from 18 months to 2 years.
•	14 January 2016	Change in the QPPV and/or QPPV contact details and/or back-up procedure